Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 106.00 |
---|---|
High | 106.00 |
Low | 106.00 |
Bid | -- |
Offer | -- |
Previous close | 106.00 |
Average volume | -- |
---|---|
Shares outstanding | 132.86m |
Free float | 118.28m |
P/E (TTM) | -- |
Market cap | 15.48bn USD |
EPS (TTM) | -4.62 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 07:13 BST.
More ▼
Announcements
- Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
- Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Vaxcyte Announces Pricing of $1.3 Billion Public Offering
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
- Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
- Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
- Vaxcyte Appoints John Furey to Board of Directors
- Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
- Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
More ▼